# Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through homologous and heterologous variants

Meriem Bekliz[1], Kenneth Adea[1], Pauline Vetter[2,3], Christiane S Eberhardt[4,5,6], Krisztina Hosszu-Fellous[2,3], Diem-Lan Vu[2], Olha Puhach[1], Manel Essaidi-Laziosi[1], Sophie Waldvogel-Abramowski[7], Caroline Stephan[7], Arnaud G. L'Huillier[8], Claire-Anne Siegrist[4], Arnaud M Didierlaurent[4], Laurent Kaiser[2,3], Benjamin Meyer[4*], Isabella Eckerle[1,2,3*]

[1]Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.

[2]Division of Infectious Diseases, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland.

[3]Geneva Centre for Emerging Viral Diseases, Geneva, University Hospital and Faculty of Medicine, Geneva, Switzerland.

[4]Center for Vaccinology and Neonatal Immunology, Department of Pathology and Immunology, University of Geneva, Switzerland

[5]Division of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of Medicine, University of Geneva

[6]Center for Vaccinology, Geneva University Hospitals, Geneva, Switzerland

[7]Transfusion Unit, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.

[8]Pediatric Infectious Diseases Unit, Department of Women, Child and Adolescent Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

*Corresponding authors*:
Isabella Eckerle,
Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland. Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland.
Tel: +41223729820;
Email: isabella.eckerle@hcuge.ch

Benjamin Meyer
Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Switzerland. Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
Tel: +41 22 379.57.80
Email: Benjamin.Meyer@unige.ch

**Abstract**

Emerging SARS-CoV-2 variants of concern/interest (VOC/VOI) raise questions about effectiveness of neutralizing antibodies derived from infection or vaccination. Here, we have assessed a total of 104 blood specimens, consisting of convalescent samples after infection with early-pandemic SARS-CoV-2 (pre-VOC) or with Alpha, Beta, Gamma or Delta, post-vaccination samples after double-dose mRNA-vaccination as well as samples after vaccine break-through infections with Delta or Omicron. Neutralization against seven authentic SARS-CoV-2 isolates (B.1, Alpha, Beta, Gamma, Delta, Zeta, Omicron) was assessed by plaque-reduction neutralization assay.

We found highest neutralization titers against the homologous (previously infecting) variant, with lower neutralization efficiency against heterologous variants. Loss of neutralization against heterologous variants showed considerably variability between convalescent groups suggesting that a variant-specific infection background influences immune escape characteristics.

Convalescent samples from pre-VOC SARS-CoV-2, Alpha, Beta, Gamma and Delta-infected individuals all showed a significant loss of neutralization for Omicron but to a varying degree (23.0-fold in Beta-convalescent up to 56.1-fold in Alpha-convalescent samples), suggesting that infection-derived immunity, independent of the infecting variant is most likely only poorly protective against Omicron. Of note, former variant of concern Zeta showed also a pronounced escape form neutralization of up to 28.2-fold in Alpha convalescent samples.

Two-dose vaccinated individuals showed robust neutralization against B.1 and only slightly lower neutralization titers for Alpha, Beta, Gamma, Delta and Zeta, with fold-change reduction for heterologous virus between 2.8 (for Alpha) to 6.9 (for Beta). In contrast to convalescent specimens, escape from neutralization for Zeta was largely restored in vaccinated individuals, while Omicron showed a strongly reduced neutralization of 85.7-fold compared to pre-VOC SARS-CoV-2.

Robust neutralization titers were observed in double-vaccinated individuals with subsequent Delta break-through infections, that also neutralized Omicron with a loss of only 12.5-fold. Individuals with an Omicron breakthrough infection showed high neutralization titers for both Delta and Omicron, with only a 1.5-fold loss for Delta neutralization. This suggests that infection with antigenically different variants can boost immunity against variants that are antigenically similar to the vaccine strain.

We conclude that for the assessment of escape from neutralization by new VOCs such as Omicron, the complexity of background immunity due to individual and regional differences needs to be taken into account. Geographic variation in the proportion of individual with infection- or vaccination-derived immunity or a combination of both could have substantial influence on the course of the pandemic. Combined infection/vaccination immunity after break-through infections could ultimately lead to broad immunity also against non-homologous variants.

**Keywords**

SARS-CoV-2, COVID19, variants of concern, Alpha, Beta, Gamma, Delta, Zeta, Omicron, PRNT, neutralization, vaccination

## Introduction

In late 2019, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Wuhan (China) causing a pandemic that led to an unprecedented international health crisis of yet unknown outcome [1, 2]. Shortly after its emergence, SARS-CoV-2 acquired the D614G mutation in the spike protein in February 2020, which quickly replaced all other circulating variants and spread worldwide. The evolutionary advantage of D614G is associated with enhanced binding to the human receptor and increased replication and thus presumably better transmissibility [3]. After largely uncontrolled transmission on a global scale during 2020, the emergence of the first variants of concern (VOCs) was observed [4]. The VOCs consist of the Alpha variant, first detected in the UK; the Beta variant, first detected in South Africa, the Gamma variant, first detected in South America, the Delta variant, first detected in India and the Omicron variant, very recently reported from South Africa [5]. Variants of concern were characterized by a rapid increase in case numbers and they quickly outcompeted earlier strains in their region of emergence. The latest emergence is the Omicron variant in late 2021 with the so far highest number of mutations compared to earlier variants and the majority of them located in the spike protein [4]. Thus, suspicion of escape from antibody responses derived from earlier variants and vaccines by Omicron is high.

In addition to VOCs, other variants were identified that were of less concern and therefore classified as variants of interest (VOI) due to aspects in their epidemiology or genetic signatures potentially leading to an altered phenotype, among them the (former) VOI Zeta that arose in parallel with the Gamma variant in South America at a time when a local surge in cases was observed but has disappeared in the meanwhile [6-10].

Currently, few treatments are widely available for SARS-CoV-2 and mostly dedicated to risk groups, therefore prevention and protection through vaccine-mediated immunity is still the proposed method for ending the pandemic [11]. Depending on countries, medium to high levels of population immunity have already been reached through vaccination or infection, but there are huge geographical differences when it comes to the proportions of the population infected, different circulation of variants against which immunity was obtained, percentage of vaccinated individuals, vaccine doses and type of vaccine used.

In light of that, it is of particular importance to evaluate the neutralizing potential of elicited antibodies against clinical isolates of VOCs/VOIs to detect immune escape variants early and understand the impact of such variants on the further course of the pandemic.

The mRNA-based vaccine Pfizer-BioNTech BNT162b2 encodes a stabilized full-length SARS-CoV-2 spike ectodomain derived from the Wuhan-Hu-1 genetic sequence and elicits

potent neutralizing antibodies [12], as does the mRNA-based vaccine Moderna mRNA-1273, encoding a stabilized prefusion SARS-CoV-2 spike protein [13]. However, emerging SARS-CoV-2 variants include multiple substitutions and deletions in the major target of neutralizing antibodies, the spike glycoprotein, including the N-terminal (NTD) and the receptor-binding domains (RBD), with the largest number of mutations of over 30 observed in the Omicron variant. This raises the question of whether neutralizing antibodies induced by early circulating strains or by current vaccines can effectively neutralize recently emerged virus variants. So far, studies indicated that mutations that have been accumulating in the spike protein, especially in the RBD, are associated with increased affinity to the human ACE2 receptor [14], as well as with resistance to neutralization from antibodies of previously infected or vaccinated patients [15]. Mutations in the RBD pose the greatest risk for making SARS-CoV-2 more infectious and able to escape antibody neutralization [14]. Virus neutralizing antibody have been shown to be a correlate of protection from SARS-CoV-2 but more insights on neutralizing responses against emerging virus variants are needed [16-19].

In this study, we investigated the neutralizing potency of a panel of authentic sera or plasma from individuals vaccinated twice with either BNT162b2 or mRNA-1273, and convalescent patients that had mild coronavirus disease 2019 (COVID-19). Patients were infected at different time points during the pandemic with either an early-pandemic (pre-VOC) SARS-CoV-2 or one of the VOCs Alpha, Beta, Gamma, Delta or Omicron. We used authentic clinical isolates for pre-VOC SARS-CoV-2 (Pangolin lineage B.1), Alpha, Beta, Gamma, Delta, Zeta and Omicron which were all isolated from patient samples collected from our routine diagnostic laboratory. We assessed the neutralizing potential against homologous and heterologous variants by live virus plaque reduction neutralization test (PRNT), widely regarded as the gold standard for the detection of SARS-CoV-2-specific neutralizing antibodies [20].

## Materials and Methods

### Setting

The laboratory of virology of the University Hospital of Geneva is participating and coordinating the SARS-CoV-2 variant and genomic surveillance funded by the Swiss Federal Office of Public Health with constantly ongoing full genome sequencing of SARS-CoV-2 positive patient samples obtained through the diagnostic unit of our Centre [21]. Up to around 400 positive patient specimens with a cycle threshold (Ct) < 32 are sequenced each week since

151 march 2021. From each variant that falls into any of the categories of variant of
152 concern/interest, at least one virus isolate is generated.

153 **Patient samples**

154 Convalescent sera or plasma during the early pandemic period (pre-VOC) were collected in the
155 context of two prospective cohort studies at the Geneva University Hospitals (HUG) and the
156 Geneva Centre for Emerging Viral Diseases (Understanding COVID study; ethics approval
157 number: CCER 2020-00516, Persistence study: ethics approval number: CCER 2020-00516).
158 In addition, anonymized left-over samples from apheresis collection of plasma (all collected in
159 2020) were available under the general informed consent of the University Hospitals of
160 Geneva.
161 Convalescent sera obtained from patients infected with a SARS-CoV-2 variant of concern
162 (Alpha, Beta, Gamma, Delta, Omicron) were collected in 2021 by contacting patients with
163 confirmed SARS-CoV-2 infection for a blood collection in the convalescent period for the
164 purpose of this study, same for vaccine-break through infections (Ethics approval number:
165 CCER 2020-02323). For each patient infected with a variant, information on the infecting virus
166 was available by full-genome sequence. No sequence information on the infecting strain was
167 available from patients infected in 2020, however the first SARS-CoV-2 variant in Switzerland
168 (Alpha) was only observed on Dec 24, 2020, and all pre-VOC samples were collected before
169 that date, thus they are considered pre-VOC. Plasma samples from vaccinated healthy
170 individuals, vaccinated with 2 doses of BNT162b2 (Pfizer/BioNTech) or mRNA-1273
171 (Moderna) vaccine at 28 days interval were available from a prospective observational study,
172 collected 30 days after the 2$^{nd}$ dose (Ethics approval number: CCER ICOVax 2021-00430).
173 Convalescent samples were only collected from individuals with RT-PCR-confirmed diagnosis
174 of SARS-CoV-2 in our diagnostic unit, and sera/plasma were collected 3-137 days after
175 diagnosis or symptom onset (days post diagnosis, DPP). All vaccinated individuals were in
176 addition tested for the presence of nucleocapsid antibodies (Elecsys® Anti-SARS-CoV-2 anti-
177 N) to screen for unrecognized infection prior to vaccination. There are no differences to be
178 expected in the PRNT regarding the use of plasma or serum, therefore both sample types are
179 used in parallel and termed "convalescent samples" throughout the manuscript.

180 **Viruses and cells.**

181 Vero-E6 and Vero E6-TMPRSS cells were cultured in complete DMEM GlutaMax I medium
182 supplemented with 10% fetal bovine serum, 1x Non-essential Amino Acids, and 1% antibiotics

183 (Penicillin/Streptomycin) (all reagents from Gibco, USA). Vero-TMPRSS were kindly
184 received from National Institute for Biological Standards and Controls (NIBSC, Cat. Nr.
185 100978).
186 All SARS-CoV-2 viruses used in this study were isolated from residual nasopharyngeal swabs
187 collected from patients presenting at the Geneva University Hospitals under general informed
188 consent of the hospital that allows usage of anonymized left-over materials. The following
189 viruses were isolated as follows: B.1, Alpha, Gamma and Zeta were isolated and propagated
190 on Vero E6. The Beta variant isolate was obtained as described previously [22]. Briefly, no
191 primary Beta isolate could be obtained on VeroE6 but only on A549 cells overexpressing
192 human ACE2 [23]. Therefore, after primary isolation, A549-hACE2 cells were mixed with
193 VeroE6 in a 1:1 ratio and inoculated with the passage 1 isolate. The next passage was done on
194 VeroE6 to generate the virus stock. The Omicron variant was primarily isolated on Vero-
195 TMPRSS cells, then transferred to Vero E6 for generation of a virus stock. All virus stocks
196 were titrated on Vero-E6 cells and full genome sequenced. Sequences of initial patient
197 specimens and virus isolates obtained were compared for acquired mutations (**Table S1**).
198 Experiments with live infectious SARS-CoV-2 followed the approved standard operating
199 procedures of our biosafety level 3 facility (BSL-3).

200 **Plaque Reduction Neutralization Test (PRNT).**

201 Following the PRNT procedure, Vero-E6 cells were seeded at a density of $4x10^5$ cells/mL in
202 24-well cell culture plates. A total of 34, 12, 8, 10 and 22 sera/plasma samples from patients
203 infected with pre-VOC SARS-CoV-2, Alpha, Beta Gamma, Delta or sera from individuals
204 vaccinated with BNT162b2/mRNA-1273, respectively, were used for determining the
205 neutralizing titers against B.1 (first pandemic wave strain containing only the D614G
206 substitution in the spike gene), Alpha, Beta, Gamma, Zeta, Delta and Omicron variants as
207 described earlier [24]. Briefly, all sera/plasma were heat-inactivated at 56°C for 30 min and
208 serially diluted in Opti-Pro serum-free medium starting from 1:10 until up to 1:5120 if
209 necessary. Sera/plasma were mixed with 50PFU of variant isolates (B.1, Alpha, Beta, Gamma,
210 Delta, Zeta and Omicron) and incubated at 37°C for 1h. All samples were run in duplicate and
211 for each neutralization experiment an infection control (no serum/plasma) and a reference
212 serum were used to ensure reproducibility between different experiments. Vero-E6 cells were
213 washed 1x with PBS and inoculated with the virus serum/plasma mixture for 1h. Afterwards,
214 the inoculum was removed and 500uL of the overlay medium also used for the plaque assays
215 was added. After incubation for 3 days at 37°C, 5% CO2, the overlay medium was removed,

216 cells were fixed in 6% formaldehyde solution for at least 1h, plates were washed 1x with PBS
217 and stained with crystal violet. Plaques were counted in wells inoculated with virus-
218 serum/plasma mixtures and compared to plaque counts in infection control wells. The 90%
219 reduction endpoint titers ($PRNT_{90}$) were calculated by fitting a 4-parameter logistics curve with
220 variable slope to the plaque counts of each serum/plasma using GraphPad Prism version 9.2.0.
221 For samples that did not reach 90% reduction at a 1:10 dilution, we extrapolated the titer until
222 a dilution of 1, i.e. undiluted sample. If the extrapolation reached a titer below 1, the sample
223 was given a value of 0.5 and considered negative.
224

225 **Results**

226 To evaluate the neutralization capacity of SARS-CoV-2 specific antibodies against SARS-
227 CoV-2 variants (pre-VOC, Alpha, Beta, Gamma, Delta, Zeta and Omicron), a panel of
228 convalescent blood specimens were used from i) individuals previously infected with pre-VOC
229 SARS-CoV-2 (n=34), ii) individuals previously infected with VOCs Alpha (n=12), Beta (n=8),
230 Gamma (n=10), Delta (n=10) iii) BNT162b2 or mRNA-1273 vaccinated individuals with (n=6)
231 and without prior infection (n=16) iv) BNT162b2 or mRNA-1273 vaccinated individuals with
232 a break-through infection with either Delta (n=4) or Omicron (n=4) variant (**Table 1**).

233 *Neutralizing capacity from infection-derived convalescent samples*

234 Geometric mean $PRNT_{90}$ titers of convalescent specimens from individuals infected with pre-
235 VOC SARS-CoV-2 were 37.3 (95%CI: 25.4-54.9) against B.1, 16.7 (95%CI: 9.7-28.8) against
236 Alpha, 14.0 (95%CI: 8.8-22.3) against Beta, 10.3 (95%CI:6.4-16.6) against Gamma, 12.0
237 (95%CI:7.0-20.3) against Delta, 1.4 (95%CI: 0.9-2.4) against Zeta, and 0.8 (95%CI:0.6-1.2)
238 against Omicron. Compared to B.1 this results in a fold-change reduction of 2.2 for Alpha, 2.7
239 for Beta, 3.6 for Gamma, 3.1 for Delta, 25.9 for Zeta and 45.6 for Omicron (**Figure 1A**). None
240 of the samples failed to neutralize the homologous virus. Only 1/34 (3%), 2/34 (6%), 3/34 (9%)
241 and 3/34 (9%) failed to neutralize Alpha, Beta, Gamma and Delta, respectively, whereas 21/34
242 (62%) and 29/34 (85%) completely failed to neutralize the Zeta and Omicron variant.

243 For patients previously infected with the Alpha variant (n=12), geometric mean $PRNT_{90}$ titers
244 were 45.5 (95%CI:34.3-60) for Alpha, 27.8 (95%CI:19.8-39.0) for B.1, 7.4 (95%CI:4.0-13.5)
245 for Beta, 3.8 (95%CI:1.6-8.7) for Gamma, 5.9 (95%CI:2.8-12.2) for Delta, 1.6 (95%CI:0.7-

246 3.6) for Zeta and 0.8 (95%CI:0.4-1.7) for Omicron. Compared to the homologous Alpha
247 variant, this results in a reduction of 1.6 (B.1), 6.2 (Beta), 12.0 (Gamma), 7.7 (Delta), 28.2
248 (Zeta) and 56.1 (Omicron). Complete loss of neutralization was observed for 3/12 (25%)
249 samples for Gamma, 1/12 (8%) for Delta, 5/12 (42%) for Zeta and 10/12 (83%) for Omicron
250 (**Fig. 1B**).
251
252 For individuals previously infected with the Beta variant (n=8), geometric mean $PRNT_{90}$ titers
253 were 20.6 (95%CI:6.8-62.6) for Beta, 6.0 (95%CI:1.3-27.2) for B.1, 2.6 (95%CI:0.4-14.9) for
254 Alpha, 2.6 (95%CI:0.4-15.8) for Gamma, 3.2 (95%CI:0.7-15.3) for Delta, 1.7 (95%CI:0.4-7.5)
255 for Zeta and 0.9 (95%CI:0.4-2.3) for Omicron. Compared to the homologous virus (Beta), this
256 results in a fold-reduction of 3.5 for B.1, 8.0 for Alpha, 7.8 for Gamma, 6.4 for Delta, 12.4 for
257 Zeta and 23.0 for Omicron. Complete loss of neutralization was observed for 1/8 (12.5) for
258 B.1, 4/8 (50%) for Alpha, 4/8 (50%) for Gamma, 3/8 (37.5) for Delta, 4/8 (50%) for Zeta and
259 6/8 (75%) for Omicron (**Fig. 1C**).
260
261 For individuals previously infected with the Gamma variant (n=10), geometric mean $PRNT_{90}$
262 titers were 55.6 (95%CI:24.1-128) for Gamma, 20.5 (95%CI:7.6-55.5) for B.1, 13.9
263 (95%CI:5.9-32.9) for Alpha, 18.3 (95%CI:8.9-37.4) for Beta, 3.2 (95%CI:1.0-10.1) for Delta,
264 10.2 (95%CI:5.2-20.2) for Zeta and 2.1 (95%CI:0.7-6.4) for Omicron. Compared to the
265 homologous virus, fold reduction in neutralization was 2.7 for B.1, 4.0 for Alpha, 3.0 for Beta,
266 17.6 for Delta, 5.4 for Zeta and 26.9 for Omicron. Complete loss of neutralization was observed
267 for 4/10 (40%) for Delta and 5/10 (50%) for Omicron (**Fig. 1D**). Of note, a rather strong loss
268 of neutralization in Gamma convalescent samples was observed for Delta, while neutralization
269 was less affected for the Zeta variant.
270
271 For individuals previously infected with Delta (n=10), geometric mean $PRNT_{90}$ titers were 72.8
272 (95%CI:33.9-156.2) for Delta, 25.1 (95%CI:14.0-45.1) for B.1, 18.4 (95%CI:9.5-35.4) for
273 Alpha, 13.2 (95%CI:7.4-23.5) for Beta, 15.0 (95%CI:7.8-28.7) for Gamma, 10.4 (95%CI:4.0-
274 26.9) for Zeta and 3.1 (95%CI:1.0-9.6) for Omicron. Fold reduction compared to homologous
275 virus (Delta) was 2.9 for B.1, 4.0 for Alpha, 5.5 for Beta, 4.9 for Gamma, 7.0 for Zeta and 23.8
276 for Omicron. Complete loss of neutralization was 1/10 (10%) for Zeta and 4/10 (40%) for
277 Omicron (**Fig. 1E**).

278 *Neutralizing capacity from post-vaccine and combined post-vaccine/infection-derived samples*

279 We investigated a total of 30 patient specimens from either double-vaccinated individuals
280 (n=16) or with combined vaccination-infection-derived immunity, either through prior
281 infection followed by vaccination, or vaccination followed by a vaccine-break through
282 infection with Delta or Omicron (n=14).
283
284 In contrast to all infection-derived convalescent samples, geometric mean $PRNT_{90}$ titers were
285 much higher for individuals double-vaccinated with either BNT162b2 or mRNA-1273 with
286 titers of 338.0 (95%CI:247.4-461.6) against B.1, 121.7 (95%CI:86.0-172.3) against Alpha,
287 49.3 (95%CI:28.1-86.8) for Beta, 62.8 (95%CI:36.0-109.5) for Gamma, 95.6 (95%CI:69.4-
288 131.7) for Delta, 78.5 (95%CI:50.4-122.5) for Zeta and 3.9 (95%CI:1.8-8.7) for Omicron. This
289 translates into a fold reduction of neutralization of 2.8 for Alpha, 6.9 for Beta, 5.4 for Gamma,
290 3.5 for Delta, 4.3 for Zeta and 85.7 for Omicron. No complete loss of neutralization was seen
291 for any VOC except Omicron in 5/16 (31%) specimens (**Fig. 2A**).
292
293 Individuals with prior SARS-CoV-2 infection before double vaccination (n=6), as determined
294 by presence of antibodies against the nucleocapsid, showed geometric mean $PRNT_{90}$ titers of
295 1190.4 (95%CI:837.8-1691) against B.1, followed by 683.2 (95%CI:516.3-904.1) for Alpha,
296 260.4 (95%CI:128.8-526.5) for Beta, 360.4 (95%CI:224.5-578.5) for Gamma, 494.1
297 (95%CI:419.4-582.1) for Delta, 351.8 (95%CI:227-545.2) for Zeta and 65.2 (95%CI:27.81-
298 153.0) for Omicron. Fold reduction in neutralization was 1.7 for Alpha, 4.6 for Beta, 3.3 for
299 Gamma, 2.4 for Delta, 3.4 for Zeta and 18.2 for Omicron. Of note, none of the specimens
300 showed complete loss of neutralization (**Fig. 2B**).
301
302 In addition, we have investigated vaccinated individuals with a break-through infection with
303 Delta (n=4) and Omicron (n=4) for neutralization against both viruses which are currently the
304 only VOCs co-circulating. For the first group, high geometric mean $PRNT_{90}$ titers of 1636
305 (95%CI: 128.2-20885) were observed for the Delta while 130.9 (95%CI:24.9-688.9) was
306 observed for Omicron. This results in a 12.5-fold reduction versus the homologous Delta, but
307 no complete loss of neutralization was observed (**Fig. 2C**). For Omicron break-through
308 infection following vaccination, geometric mean $PRNT_{90}$ titers were 913.5 (95%CI:341.8-
309 2442) was observed for Omicron, and 627.9 (95%CI:269.5-1463) was observed for Delta,
310 which equals a 1.5-fold loss of neutralization to heterologous Delta (**Fig. 2 D**). Highest titers
311 were seen against the infecting variant Omicron compared to Delta, although the prior vaccine-
312 derived immunity by an early pandemic spike is antigenically closer to Delta than to Omicron.

*Individual profiles of SARS-CoV-2 homologous and heterologous neutralization*

In addition to cumulated data (**Fig. 1 and 2**), neutralization profiles were also displayed on an individual basis (**Figure S1-S9**). Here, inter-individual differences both in quantity of antibody response as well as patterns of neutralization loss towards heterologous variants were observed, which does not necessarily reflect pooled results in all individuals. For example, while neutralization against Omicron was the lowest throughout convalescent samples, the differences between Alpha, Beta and Gamma were less pronounced in some individuals. Of note, in all individual comparisons, the most efficient neutralization was always observed against the homologous (infecting) strain through all convalescent sera as well as vaccine sera, when considering that the vaccine Spike most closely resembles the early pandemic variant B.1.

## Discussion

Here we assess neutralizing capacity towards seven SARS-CoV-2 variants by convalescent specimens from individuals recovered from infection with the early-pandemic strain (pre-VOC) or the VOCs Alpha, Beta, Gamma or Delta, from double-vaccinated individuals either with or without prior infection and from double-vaccinated individuals infected with the Delta or Omicron variant.

We could show that highest SARS-CoV-2 neutralizing titers, either elicited through infection of vaccination, were always observed against the homologous strain (infecting strain or antigen used in the vaccine formulation), whereas a reduced neutralizing capacity was found for heterologous strains.

In agreement with our results, one study found lower neutralization for the Alpha and Gamma variant by pre-VOC convalescent sera and lower neutralization for pre-VOC and Alpha in Gamma infected patients, but reduced neutralization only for Gamma in vaccine sera (3.3-fold [25]. In line with these observations, Alpha-infected individuals showed reduced neutralization for the Beta variant [26]. Reduction in neutralization capacity for the Delta variant was estimated between 4- and 8-fold in vaccinated and 6-fold in convalescent sera [27]. Beyond our study, there is only a single pre-print that investigated the response to VOCs in a background

344 of variant-specific convalescent samples from individuals infected with pre-VOC, Alpha, Beta
345 or Delta samples, that showed strongest neutralization towards homologous vs heterologous
346 virus for Alpha, Beta and Delta convalescent-variant pairs. [28]

347 We observed a reduction of neutralization capacity by first-wave SARS-CoV-2 convalescent
348 and post-vaccine samples towards Alpha, Beta, Gamma and Delta to a comparable extent than
349 what was described by others [27, 29-32]. While for the Alpha variant, only slightly reduced
350 neutralization was described for both convalescent and vaccinee sera, a more pronounced
351 reduction of neutralization was observed for the Beta and Gamma variant [30, 31, 33-36]. Thus,
352 Beta and Gamma comprised the two VOCs with the most pronounced immune escape and at
353 the same time successful enough to cause larger outbreaks in defined geographic region,
354 without reaching global dominance in the time before the emergence of Omicron. A recent
355 study with pre-VOC SARS-CoV-2, Alpha and Beta in multiple animal and cell culture models
356 showed enhanced fitness of Alpha but not Beta which could be a reason why Alpha but not
357 Beta reached wide dominance in early 2021 [37].

358 Across our panel of convalescent and vaccine sera, the strongest decline of neutralization
359 capacity was observed for Zeta and Omicron. While convalescent specimens showed strong
360 reduction of neutralization for Zeta of up to 25.9-fold, neutralization capacity was restored in
361 vaccinated individuals that showed only 4.3-fold decline compared to pre-VOC SARS-CoV-
362 2. In contrast, for Omicron, a stark loss of neutralizing activity of up to 46-fold or 86-fold was
363 observed for both convalescent and vaccine sera, respectively. Thus, fold-change reduction
364 was even higher in vaccine sera than in convalescent sera, although titer in vaccine sera were
365 higher and therefore percentage of specimens with complete loss was lower (31% of specimens
366 vs. 83%). A similar loss of neutralization capacity against Omicron was observed in other
367 studies [28, 38-40], although no validation across the full range of VOC convalescent sera was
368 available before our data set. Interestingly, immune escape properties in terms of fold change
369 reduction vs. the homologous virus was overlapping between Zeta and Omicron in some
370 combinations, e.g. a 25.9-fold reduction of Zeta in pre-VOC convalescent samples, and a 23.0-
371 fold reduction of Omicron in Beta convalescent samples. Such observed differences in fold-
372 change reduction between Zeta and Omicron were less than 2-fold in early pandemic, Alpha
373 and Beta convalescent sera, showing that even before the emergence of Omicron, variants with
374 strong immune escaping properties almost reaching that of Omicron were already circulating
375 but did not become dominant. For post-Gamma and post-Delta specimens, the differences

376 between fold-change reduction of Zeta and Omicron were much bigger, with Omicron showing
377 a 3-5-fold higher escape of neutralization compared to Zeta. At least for Gamma, robust
378 neutralization for Zeta could be explained by a common origin as both are descendants from
379 B.1.1.28 (Pango lineage) [10]. To the best of our knowledge, no data on neutralization of the
380 Zeta variant by convalescent or vaccinee samples has been described to date, and few other
381 data were obtained on this variant. Contrary, loss of neutralization for Delta was much more
382 pronounced in Gamma than in any other convalescent or vaccine sera with a 17.6-fold
383 reduction. Such strong immune escape of Delta in a variant-specific infection background has
384 not been reported before.

385 Of note, we have observed large differences in the reduction of neutralization capacity across
386 specimens with different infection background which has not been described in this detail
387 before. While convalescent specimens of individuals infected with a pre-VOC SARS-CoV-2
388 and Alpha showed 45.6- and 56.1-fold reduction of neutralization capacity for Omicron,
389 patients previously infected with the Beta, Gamma or Delta variant showed a lower reduction
390 in neutralization capacity of 23.0, 26.9 and 23.8-fold, and a lower percentage of specimens
391 with complete neutralization failure, respectively. These differences could indicate that
392 regional heterogeneity in background immunity could potentially influence emergence and
393 spread of Omicron or other future variants with immune escape properties.

394 A gradient of immune escape can be described from the variants investigated here, from pre-
395 VOC to Alpha (only slight immune escape, but successfully outcompeted earlier strains), Beta
396 and Gamma (more pronounced immune escape with regionally pronounced circulation but no
397 global dominance) to Zeta (variant with one of the strongest escapes of immunity prior to
398 Omicron, but limited transmission). Our data on Zeta, along with data two other VOIs Mu and
399 Lambda, have shown the strongest escape from neutralization in pandemic period before the
400 emergence of Omicron [41-44]. Although differences between escape from neutralization
401 between Zeta and Omicron are only two-fold in some subgroups, neutralization for Zeta was
402 restored in vaccinee specimens, while this was not the case for Omicron. This could hint
403 towards different mechanisms of immune escape between SARS-CoV-2 variants.

404 Of note, mutation of position 484 in the receptor binding domain is found in Beta, Gamma,
405 Zeta (E484K) and Omicron (E484A). The same mutation arose independently also in a lineage
406 of the Alpha variant where is was also associated with escape from neutralizing antibodies[45].
407 It has been shown that a mutation at position 484 of the spike tends to have the strongest effect

408 on receptor binding and neutralization [46-49]. While the mutation can explain, at least partly,
409 the strong escape from neutralization in Omicron, it has no or only very low influence on
410 ACE2-binding and is therefore most likely not associated with higher transmissibility, although
411 the mechanism of transmissibility in Omicron is not well understood [50].

412 We have shown that Omicron exhibits a strong escape from neutralization in both convalescent
413 and vaccine sera, although differences in fold change reduction exist depending on prior
414 infection background. However, it has been shown that a third dose of a mRNA vaccine is able
415 to restore neutralizing capacity [51-54]. Similarly, individuals with mixed immunity, i.e.
416 infection prior to double vaccination, or infection after double vaccination, also leads to higher
417 neutralizing capacity towards Omicron [40,Rössler, 2021 #90]. With an increasing number of
418 vaccine break-through infections observed during the Delta wave and reports of a large number
419 of vaccine break-through infections with Omicron, an assessment of mixed immunity is of
420 huge interest, especially for protection against new variants [55]. In addition, it has been
421 speculated whether the immune response towards an antigenically drifted SARS-CoV-2 variant
422 will be influenced by pre-existing immunity [56].

423 Here we investigated four individuals with a Delta break-through infection after double
424 vaccination and have found high neutralizing titers for Delta. Neutralization capacity for
425 Omicron was markedly reduced, but titers were still higher than titers against other VOCs in
426 double-vaccinated individuals indicating that even a boost with a mismatched strain (Delta)
427 can lead to a considerable increase in immunity against Omicron. Similarly, vaccine break
428 through infections with Omicron resulted in very high neutralization titers against the Omicron
429 variant indicating that infection with an antigenically drifted variant led to a robust Omicron-
430 specific immune response despite the presence of pre-existing immunity against the original
431 pandemic strain. Interestingly, neutralizing titers against the Delta variant were only minimally
432 reduced compared to Omicron indicating that infection with antigenically different variants can
433 boost immunity against variants that are antigenically similar to the vaccine strain.

434 Population immunity and evolutionary pressure might differ on a regional scale depending on
435 the immunity induced by earlier circulating variants [57]. High titers of neutralizing antibodies,
436 such as elicited by the vaccine, were at least partially able to neutralize earlier variants before
437 the rise of Omicron. Form an epidemiological point of view, this highlights that vaccine-
438 induced immunity probably would have allowed lower virus circulation compared to immunity
439 induced through infections, which may have prevented the evolution of new variants that

440 harbor immune escape properties such as Omicron. Although the origin of Omicron is not well
441 understood, it was speculated that a high background of Beta-variant immunity has favored the
442 development of Omicrons immune escaping properties [58]. In contrast to earlier variants,
443 Omicron is showing a rapid increase in cases with a short doubling time, in addition to its
444 immune-escaping properties [59]. This, together with reduced neutralization is also suggestive
445 of decreased vaccine effectiveness, will further complicate the management of the pandemic.

446 Limitations of our study are the relatively low number of specimens that were available for
447 convalescent specimens of patients previously infected with variants. Furthermore, we cannot
448 exclude that individuals infected with a VOC have not already been infected in 2020 with a
449 first-wave virus and thus antibodies are derived from multiple infections with more than one
450 variant. In addition, the Beta variant, which could not be readily isolated on VeroE6 cell lines
451 had to be adapted to VeroE6 in order to be usable for our PRNT, thus the isolate accumulated
452 mutations, which could affect the neutralization results. No convalescent samples were
453 available from individuals infected with Zeta, and no convalescent samples were yet available
454 from individuals infected with Omicron without prior vaccination. Furthermore, testing of
455 single time points after infection/vaccination can only provide a snapshot and not inform on
456 the duration of antibody responses over time. All our blood specimens were collected at rather
457 early time points after infection or vaccination, thus with time, a broader neutralizing capacity
458 towards the heterologous variant might be observed due to somatic hypermutation and affinity
459 maturation, although in the case of Omicron most likely will not restore neutralization loss
460 [60].

461 Overall, we could show that responses to variants before Omicron were associated with
462 reduced, but not complete loss in neutralization both by infection-derived as well as vaccine
463 derived immunity, although variants such as Zeta have already shown immune escape
464 properties, but did not become dominant at the time of their emergence. Omicron, in contrast
465 to earlier variants displays a strong immune escape with a surge in case numbers in many areas
466 of the world. Furthermore, the continuous emergence of SARS-CoV-2 variants since late 2020
467 shows that the virus is still underlies evolutionary pressure and currently available vaccines
468 might not be sufficient to mitigate the pandemic in the near-term future. Furthermore, whether
469 immunity of a population was obtained by a vaccine or by previous infection with a certain
470 SARS-CoV-2 variants could influence the type of evolutionary pressure for circulating SARS-

CoV-2 and lead to the emergence of new variants that differ for countries with major vaccine vs. major infection-derived immunity.

**Acknowledgments**

We thank Pascale Sattonnet-Roche for excellent technical help. We thank the staff of the laboratory of virology at the HUG for help with sample collection and identification. We thank all clinicians and technical staff of the different clinical cohorts for their help. We are grateful for the patients who were willing to donate their samples and agree to participate in the studies and to help us conduct this study.

We thank Samuel Cordey and Florian Laubscher for help with sequence analysis. We thank Mirco Schmolke and Beryl Mazel-Sanchez for A549-hACE2 cells.

We thank Volker Thiel, Jenna Kelly and Silvio Steiner, Vetsuisse Bern, for help with Omicron sequencing.

**Funding**

This work was supported by the Swiss National Science Foundation 196644, 196383, NRP (National Research Program) 78 Covid-19 Grant 198412, the Fondation Ancrage Bienfaisance du Groupe Pictet and the Fondation Privée des Hôpitaux Universitaires de Genève.

| *Convalescent cohort* | | | | | | |
|---|---|---|---|---|---|---|
| **Infecting virus** | **Number patient** | **Gender (M/F)** | **Age, mean (range)** | **DPP/DPOS** | **Sample type** | **Infection period** |
| **pre-VOCs** | 34 | 20/14 | 31 (6-63) | 32 (25-37)* | Serum, Plasma | March-June 2020 |
| **Alpha** | 12 | 8/4 | 51 (25-88) | 27 (8-42) | Serum | December 2020-February 2021 |
| **Beta** | 8 | 2/6 | 42 (20-61) | 50 (3-98) | Serum | January-May 2021 |
| **Gamma** | 10 | 4/6 | 44 (20-51) | 54 (7-137) | Serum | January-April 2021 |
| **Delta** | 10 | 4/6 | 42 (27-59) | 71 (9-118) | Serum | May-July 2021 |
| *Vaccinated cohort* | | | | | | |
| **Vaccine** | **Number of patient** | **Gender (M/F)** | **Age mean (range)** | **DPV** | **Sample type** | **Date of vaccination** |
| **mRNA vaccine** | 16 | 4/12 | 52 (36-62) | 30 | Serum, Plasma | March-May 2021 |
| *Vaccinated and infected individuals* | | | | | | |
| **Vaccination/infection status** | **Number of patient** | **Gender (M/F)** | **Age mean (range)** | **DPV** | **Sample type** | **Intervall vaccination – infection** Mean weeks (range) |
| **Prior infection + 2x vaccination** | 6 | 3/3 | 46 (26-60) | n.a | Serum | n.a. |
| **2x vaccination + break through (Delta)** | 4 | 2/2 | 42 (29-54) | 48 (37-60) | Serum | 20 (11-28) |
| **2x vaccination + break through (Omicron)** | 2 | 1/1 | 31 (12-50) | 16 (16-16) | Serum | 23 (23-27) |
| **1x vaccination + break through (Omicron)** | 2 | 2/0 | 13 (12-14) | 16 (16-16) | Serum | 3 (3) |

489 **Table 1.** Characteristic of sample cohorts used in this study. DPP, days post diagnosis, DPOS, days post symptom onset (marked with *) DPV, days post 2nd
490 dose vaccination, n.a. not accessible

491 **Figures**




492

493 **Figure 1.** Neutralization in infection-derived blood specimens against seven authentic isolates
494 of SARS-CoV-2 variants (B.1, Alpha, Beta Gamma, Delta, Zeta, Omicron). Bars represent
495 geometric mean titers (GMT) of 90% reduction endpoint titers ($PRNT_{90}$) with 95% confidence
496 interval. Convalescent specimens are derived from individuals infected with (**A**) early-
497 pandemic SARS-CoV-2 (pre-VOC), (**B**) Alpha (**C**) Beta (**D**) Gamma (**E**) Delta. Colored
498 numbers above bars refer to fold change reduction of GMT versus the homologous (infecting)
499 variant, shown as first bar of each figure. Colored numbers below each bar represents number
500 of specimens with complete loss of neutralization ($PRNT_{90}$ titer < 1).




**Figure 2.** Neutralization in infection-derived blood specimens against seven authentic isolates of SARS-CoV-2 variants (B.1, Alpha, Beta Gamma, Delta, Zeta, Omicron). Bars represent geometric mean titers (GMT) of 90% reduction endpoint titers ($PRNT_{90}$) with 95% confidence interval. Cohorts consist of individuals with (**A**) double-dose mRNA vaccination, (**B**) prior SARS-CoV-2 infection followed by double-dose mRNA vaccination (**C**) Delta break-through infection of double-vaccinated individuals and (**D**) Omicron break-through infection following double (n=2) and single (n=2) mRNA vaccination. Colored numbers above bars refer to fold change reduction of GMT versus the homologous (infecting) variant, shown as first bar of each

510 figure. Colored numbers below each bar represents number of specimens with complete loss
511 of neutralization ($PRNT_{90}$ titer < 1).

512

513 **Supplementary data**

514 **Figure S1.** Distribution of neutralizing antibodies titers of each individual's pre-VOC
515 convalescent-serum/plasma against variants of SARS-CoV-2.

516 **Figure S2.** Distribution of neutralizing antibodies titers of each individual's serum of prior
517 Alpha infection against variants of SARS-CoV-2.

518 **Figure S3.** Distribution of neutralizing antibodies titers of each individual's serum of prior Beta
519 infection against variants of SARS-CoV-2.

520 **Figure S4.** Distribution of neutralizing antibodies titers of each individual's serum of prior
521 Gamma infection against variants of SARS-CoV-2.

522 **Figure S5**. Distribution of neutralizing antibodies titers of each individual's serum of prior
523 Delta infection against variants of SARS-CoV-2.

524 **Figure S5.** Distribution of neutralizing antibodies titers of each individual's vaccine-
525 serum/plasma against variants of SARS-CoV-2.

## References


1. Zhu, N., et al., *A Novel Coronavirus from Patients with Pneumonia in China, 2019.* N Engl J Med, 2020. **382**(8): p. 727-733.
2. Zhou, P., et al., *A pneumonia outbreak associated with a new coronavirus of probable bat origin.* Nature, 2020. **579**(7798): p. 270-273.
3. Zhou, B., et al., *SARS-CoV-2 spike D614G change enhances replication and transmission.* Nature, 2021. **592**(7852): p. 122-127.
4. World Health Organization, 08.12.2021]; Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
5. Viana, R., et al., *Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.* medRxiv, 2021: p. 2021.12.19.21268028.
6. Tegally, H., et al., *Detection of a SARS-CoV-2 variant of concern in South Africa.* Nature, 2021. **592**(7854): p. 438-443.
7. Davies, N.G., et al., *Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.* Science, 2021. **372**(6538).
8. Campbell, F., et al., *Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.* Euro Surveill, 2021. **26**(24).
9. Faria, N.R., et al., *Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil.* Science, 2021. **372**(6544): p. 815-821.
10. Voloch, C.M., et al., *Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil.* J Virol, 2021.
11. NIH, 08.12.2021]; Available from: https://www.covid19treatmentguidelines.nih.gov
12. Walsh, E.E., et al., *Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.* N Engl J Med, 2020. **383**(25): p. 2439-2450.
13. Jackson, L.A., et al., *An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.* N Engl J Med, 2020. **383**(20): p. 1920-1931.
14. Wang, R., et al., *Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.* Genomics, 2021. **113**(4): p. 2158-2170.
15. Hoffmann, M., et al., *SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.* Cell, 2021. **184**(9): p. 2384-2393 e12.
16. Addetia, A., et al., *Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.* J Clin Microbiol, 2020. **58**(11).
17. Khoury, D.S., et al., *Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.* Nat Med, 2021. **27**(7): p. 1205-1211.
18. Earle, K.A., et al., *Evidence for antibody as a protective correlate for COVID-19 vaccines.* Vaccine, 2021. **39**(32): p. 4423-4428.
19. Huang, A.T., et al., *A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease.* medRxiv, 2020.
20. Chmielewska, A.M., et al., *Immune response against SARS-CoV-2 variants: the role of neutralization assays.* NPJ Vaccines, 2021. **6**(1): p. 142.
21. Federal Office of Public Health Switzerland 2021 08.12.2021]; Available from: https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-83732.html.
22. Ulrich, L., et al., *Enhanced fitness of SARS-CoV-2 variant of concern B.1.1.7, but not B.1.351, in animal models.* bioRxiv, 2021: p. 2021.06.28.450190.

23. Ilmjarv, S., et al., *Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant.* Sci Rep, 2021. **11**(1): p. 13705.
24. Meyer, B., et al., *Validation of a commercially available SARS-CoV-2 serological immunoassay.* Clin Microbiol Infect, 2020. **26**(10): p. 1386-1394.
25. Gidari, A., et al., *Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.* J Infect, 2021. **83**(4): p. 467-472.
26. Faulkner, N., et al., *Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.* Elife, 2021. **10**.
27. Davis, C., et al., *Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.* PLoS Pathog, 2021. **17**(12): p. e1010022.
28. Rössler, A., et al., *SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals.* medRxiv, 2021: p. 2021.12.08.21267491.
29. Hojjat Jodaylami, M., et al., *Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins.* Sci Rep, 2021. **11**(1): p. 21601.
30. Muik, A., et al., *Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.* Science, 2021. **371**(6534): p. 1152-1153.
31. Shen, X., et al., *Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.* N Engl J Med, 2021. **384**(24): p. 2352-2354.
32. Mlcochova, P., et al., *SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion.* Nature, 2021. **599**(7883): p. 114-119.
33. Edara, V.V., et al., *Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.* Cell Host Microbe, 2021. **29**(4): p. 516-521 e3.
34. Skelly, D.T., et al., *Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.* Nat Commun, 2021. **12**(1): p. 5061.
35. Wang, P., et al., *Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.* Cell Host Microbe, 2021. **29**(5): p. 747-751 e4.
36. Bates, T.A., et al., *Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples.* JAMA, 2021.
37. Ulrich, L., et al., *Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta.* Nature, 2021.
38. Dejnirattisai, W., et al., *Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum.* medRxiv, 2021: p. 2021.12.10.21267534.
39. Cele, S., et al., *SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection.* medRxiv, 2021: p. 2021.12.08.21267417.
40. Wilhelm, A., et al., *Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies.* medRxiv, 2021: p. 2021.12.07.21267432.
41. Acevedo, M.L., et al., *Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda.* medRxiv, 2021: p. 2021.06.28.21259673.
42. Xie, X., et al., *Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies.* Zool Res, 2021. **42**(6): p. 789-791.
43. Uriu, K., et al., *Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.* N Engl J Med, 2021. **385**(25): p. 2397-2399.
44. Liu, H., et al., *The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines.* bioRxiv, 2021.
45. Collier, D.A., et al., *Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.* Nature, 2021. **593**(7857): p. 136-141.

623 46. Greaney, A.J., et al., *Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding*
624 *domain that affect recognition by polyclonal human plasma antibodies.* Cell Host Microbe,
625 2021. **29**(3): p. 463-476 e6.
626 47. Andreano, E., et al., *SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19*
627 *convalescent plasma.* bioRxiv, 2020.
628 48. Liu, Z., et al., *Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that*
629 *attenuate monoclonal and serum antibody neutralization.* bioRxiv, 2021.
630 49. Weisblum, Y., et al., *Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.*
631 Elife, 2020. **9**.
632 50. Starr, T.N., et al., *Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals*
633 *Constraints on Folding and ACE2 Binding.* Cell, 2020. **182**(5): p. 1295-1310 e20.
634 51. Garcia-Beltran, W.F., et al., *mRNA-based COVID-19 vaccine boosters induce neutralizing*
635 *immunity against SARS-CoV-2 Omicron variant.* medRxiv, 2021.
636 52. Doria-Rose, N.A., et al., *Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape*
637 *from Neutralizing Antibodies.* medRxiv, 2021.
638 53. Nemet, I., et al., *Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection.*
639 medRxiv, 2021: p. 2021.12.13.21267670.
640 54. Yu, X., et al., *Enhanced neutralization against SARS-CoV-2 by vaccine booster exhibits*
641 *reduction of Omicron variant.* medRxiv, 2021: p. 2021.12.17.21267961.
642 55. Eggink, D., et al., *Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in*
643 *vaccinated and previously infected individuals, the Netherlands, 22 November to 19 December*
644 *2021.* medRxiv, 2021: p. 2021.12.20.21268121.
645 56. Brown, E.L. and H.T. Essigmann, *Original Antigenic Sin: the Downside of Immunological*
646 *Memory and Implications for COVID-19.* mSphere, 2021. **6**(2).
647 57. Karuna, S., et al., *Neutralizing antibody responses over time in demographically and clinically*
648 *diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A*
649 *cohort study.* PLoS Med, 2021. **18**(12): p. e1003868.
650 58. Zahradnik, J., et al., *Receptor binding and escape from Beta antibody responses drive Omicron-*
651 *B.1.1.529 evolution.* bioRxiv, 2021: p. 2021.12.03.471045.
652 59. Yang, W. and J. Shaman, *SARS-CoV-2 transmission dynamics in South Africa and*
653 *epidemiological characteristics of the Omicron variant.* medRxiv, 2021: p.
654 2021.12.19.21268073.
655 60. Gaebler, C., et al., *Evolution of antibody immunity to SARS-CoV-2.* Nature, 2021. **591**(7851): p.
656 639-644.

657

# Supplementary data

**Bekliz M et al.**

**Neutralization of ancestral SARS-CoV-2 and its variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through homologous and heterologous variants**

**Table S1.**

| | B.1 | Alpha | Beta | Gamma | Delta | Zeta | Omicron |
|---|---|---|---|---|---|---|---|
| **Virus name** | hCoV-19/Switzerland/GE-SNRCI-29943121/2020 | hCoV-19/Switzerland/2012212272/2020 | hCoV-19/Switzerland/GE-33128281/2021 | hCoV-19/Switzerland/GE-33115015/2021 | hCoV-19/Switzerland/GE-33896105/2021 | hCoV-19/Switzerland/GE-32966260/2021 | hCoV-19/Switzerland/VD-HUG-36221084/2021 |
| **GISAID accession ID** | EPI_ISL_414019 | EPI_ISL_2131446 | EPI_ISL_981782 | EPI_ISL_981707 | EPI_ISL_1811202 | EPI_ISL_897700 | EPI_ISL_7605546 |
| **Location** | Europe / Switzerland / Geneva | Europe / Switzerland | Europe / Switzerland / Geneva | Europe / Switzerland / Geneva | Europe / Switzerland / Geneva | Europe / Switzerland / Geneva | Europe / Switzerland / Vaud |
| **Host** | Human | Human | Human | Human | Human | Human | Human |
| **Collection date** | 27.02.2020 | 23.12.2020 | 31/01/2021 | 29.01.2021 | 17.04.2021 | 14.01.2021 | 30.11.2021 |
| **Clade** | G | GRY | GH | GR | GK | G | GRA |
| **Pango lineage** | B.1 | B.1.1.7 | B.1.351 | P.1 | AY.122 | P.2 | BA.1 |

**Figure S1.**

## Convalescent pre-VOC *(n=34)*



**Figure S1.**

## Convalescent pre-VOC *(n=34)*



**Figure S1.**

## Convalescent pre-VOC *(n=34)*



**Figure S2.**

## Convalescent Alpha *(n=12)*



**Figure S3.**

## Convalescent Beta *(n=8)*



**Figure S4.**

## Convalescent Gamma *(n=10)*



**Figure S5.**

## Convalescent Delta *(n=10)*



**Figure S6.**

## Vaccine 2 doses *(n=16)*



**Figure S6.**

## Vaccine 2 doses *(n=16)*



**Figure S7.**

## Vaccine 2 doses + prior infection *(n=6)*



**Figure S8.**

## Vaccine Delta break through *(n=4)*



**Figure S9.**

## Vaccine Omicron break through *(n=4)*